US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Articles published by Biocartis NV

News headline image
Press Release Biocartis NV: Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis Announces Agreement with City of Hope to Explore Development of Rapid Gene Signature Test for Early Detection of Pancreatic Cancer
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis to Collaborate with Medical College of Wisconsin on Breast Cancer Gene Signatures
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis Receives European IVDR Certification for the Idylla™ CDx MSI Test
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis Showcases Growing Impact of Idylla™ Platform at AMP 2025
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis Welcomes Mike Kreitzinger as Senior Vice President of Global Business Development
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis Welcomes Ben Svarczkopf as Senior Vice President of Global Marketing
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation Assay
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis Announces Multiple Abstracts Demonstrating the Impact of Idylla™ in Oncology Diagnostics to be Presented at USCAP 2025 Annual Meeting
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis announces new data on early CAR-T vector load assessment with Idylla™ presented at ASTCT: A Potential Breakthrough in LBCL Treatment Monitoring
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis appoints Randy Polonsky as Chief Financial Officer
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis announces six Idylla™ abstracts to be presented at AMP 2024 Annual Meeting
From Biocartis NV
Via GlobeNewswire
News headline image
Press release Biocartis NV: Biocartis appoints renowned precision oncology expert, Dr. W. Michael Korn, as Chief Medical and Scientific Officer
From Biocartis NV
Via GlobeNewswire
News headline image
Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing
From Biocartis NV
Via GlobeNewswire
News headline image
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region
From Biocartis NV
Via GlobeNewswire
News headline image
Press release Biocartis Group NV: Biocartis Announces Nine Idylla™ Studies to be Published at Upcoming AMP 2022 Annual Meeting
From Biocartis NV
Via GlobeNewswire